Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Comments

Loading...

PharmaTher Holdings Stock News

PHRRFOTCQB

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$0.1640

0.009005.81%

At close: -

$0.1649

0.000900.55%

After Hours: May 13, 9:29 AM EDT

PharmaTher Holdings (PHRRF) Forecast

News

Earnings PharmaTher Holdings (PHRRF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest PharmaTher Holdings Stock News | OTC:PHRRF | Benzinga

Get the latest news on PharmaTher Holdings stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on PharmaTher Holdings performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Monday, January 15, 2024

Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
Lara Goldstein

Monday, October 02, 2023

Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
Lara Goldstein

Wednesday, September 27, 2023

PharmaTher Is 'One Step Closer To Being A Ketamine Leader' Due To FDA Acceptance
Lara Goldstein

Tuesday, September 12, 2023

Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years, NY Consulting Firm Predicts
Lara Goldstein

Monday, September 11, 2023

Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
Lara Goldstein

Wednesday, September 06, 2023

PharmaTher Aims To Mitigate Ketamine Shortage With New FDA Application
Lara Goldstein

Monday, July 24, 2023

Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More
Lara Goldstein

Tuesday, July 18, 2023

PharmaTher's DMT Patch Shows Positive Outcomes, Investment Toward The Clinical Stage
Lara Goldstein

Tuesday, July 04, 2023

Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
Lara Goldstein

Wednesday, June 28, 2023

BetterLife Fast Tracks Its US Patent For Non-Hallucinogenic Compound And Other LSD Derivatives
Lara Goldstein

Tuesday, June 27, 2023

Ketamine News: PharmaTher Begins FDA Filing For KETARX Application, Stella Acquires Field Trip Assets
Lara Goldstein

Wednesday, June 21, 2023

PharmaTher's Novel Ketamine Heads For The US Market With New Collaboration Agreement
Lara Goldstein

Monday, May 08, 2023

Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
Lara Goldstein

Wednesday, May 03, 2023

Parkinson's Patients May Benefit From Ketamine, PharmaTher Applies For FDA Fast Track
Nicolás Jose Rodriguez

Wednesday, April 05, 2023

Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More
Lara Goldstein

Monday, April 03, 2023

MDMA Transdermal Patch Moves Toward First-In-Human Trials: Latest Development Update
Lara Goldstein

Thursday, March 30, 2023

Ketamine Company Advances Parkinson's Treatment Through Final Stages Toward FDA Approval
Lara Goldstein

Tuesday, February 28, 2023

Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
Lara Goldstein

Wednesday, February 22, 2023

Development Of DMT Transdermal Patch With Eye Disease Treatment In Mind
Lara Goldstein

Monday, February 13, 2023

Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More
Lara Goldstein

Tuesday, February 07, 2023

PharmaTher Seeks Regulatory Approval Of New Ketamine Delivery System For Anesthesia And Sedation
Lara Goldstein

Monday, February 06, 2023

Psyched: Australia Legalizes Psychedelics Therapy, BC's Decrim, State Bills, Millions For Trials & Clinics
Lara Goldstein
MDMA News: Optimi's New Drug Now Available, Revive Advances Transdermal Patch Evaluations
Lara Goldstein

Friday, February 03, 2023

PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch
Lara Goldstein

Wednesday, January 25, 2023

Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
Lara Goldstein

Saturday, January 21, 2023

Search Is On For Psychedelic Patents & FDA Designations, 3 Companies Share News
Lara Goldstein

Thursday, January 19, 2023

Psychedelics Market Could Reach $12B By 2029, Says New Report
Lara Goldstein

Wednesday, January 11, 2023

2 Psychedelics Companies Tout Advanced Clinical Trials, Progress With Key Products
Lara Goldstein

Thursday, December 15, 2022

FDA OKs Ketamine For Treating Organ Transplant Injuries With 'Orphan Drug' Status
Lara Goldstein

Tuesday, November 01, 2022

Ketamine Could Soon Be A Treatment Option For This Rare Genetic Neurological Disorder
Lara Goldstein

Wednesday, October 05, 2022

Ketamine for Parkinson's Disease, PharmaTher Holdings Announces Grant of U.S. Patent To Cover It
Joana Scopel

Thursday, September 29, 2022

PharmaTher Provides Business Highlights And Releases Audited Annual Financials
Lara Goldstein

Saturday, September 17, 2022

PharmaTher Presents Positive Data On Ketamine For Treatment Of Dyskinesia In Parkinson's Disease
Nicolás Jose Rodriguez

Wednesday, September 07, 2022

Intradermal Ketamine Patch Completes Pre-Clinical Phase, Advances To Clinical Studies
Lara Goldstein

Wednesday, July 13, 2022

PharmaTher Receives Notice Of Allowance For U.S. Patent Covering Ketamine For Parkinson's And Motor Disorders Treatment
Lara Goldstein

Wednesday, June 29, 2022

PharmaTher's Preclinical Trial For Ketamine Micro-Needle Patch Shows Positive Results For Dosing
Lara Goldstein

Thursday, June 02, 2022

These 18 Clinical Trials Could Shape The Future Of The Psychedelics Industry
Natan Ponieman

Thursday, May 26, 2022

More Synergies On The Go: New Wearable Ketamine Delivery Device by PharmaTher & CCBIO
Lara Goldstein

Tuesday, May 10, 2022

Psyched: Protesters At DEA HQ Demand Access To Psychedelics, Connecticut Approves Budget Bill With MDMA & Psilocybin Programs
Natan Ponieman

Thursday, May 05, 2022

Pharmather Lands US Patent To Formulate, Produce Ketamine With This New Process
Fermin Orgambide

Monday, May 02, 2022

Psyched: Elon Musk Praises Psychedelics Over Antidepressants, Field Trip To Split In Two, Colorado MDMA Bill Moves Forward
Natan Ponieman

Tuesday, April 26, 2022

Pharmather Reports Improved Q3 Results, Continues Ketamine Trials For Epilepsy
Fermin Orgambide

Thursday, March 24, 2022

Ketamine Could Help Treat Parkinson's Disease...
Benzinga Newsdesk

Tuesday, January 25, 2022

Psychedelic Medicine Co. PharmaTher Provides Update On Pipeline And Milestones For 2022
Microdose Psychedelic Insights

Wednesday, January 12, 2022

FDA Approves PharmaTher's Phase 2 Trial For Ketamine ALS Treatment
Aaron Bry

Monday, November 08, 2021

Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
Natan Ponieman

Monday, October 18, 2021

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
Natan Ponieman
A Look At PharmaTher And Its Recent Bull Run: Where's The Psychedelics Stock Headed?
Microdose Psychedelic Insights

Wednesday, October 13, 2021

There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Natan Ponieman

Monday, October 11, 2021

Psyched: Seattle Decriminalizes Psychedelics, Psilocybin Increases Emotions From Music, Novamind's Palliative Care Program
Natan Ponieman

Connect With Us

About Benzinga

About Us
Careers
Advertise
Contact Us

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Benzinga Pro Trading Platform
Options Trading Strategies and News
Stock Market Trading Ideas and Analysis
Technical Analysis Charts and Indicators
Fundamental Analysis and Valuation
Day Trading Guides and Strategies
Live Investors Events
Pre market Stock Analysis and News
Cryptocurrency Market Analysis and News

Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved